| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $115.1M | — | +142.6% |
| Cost of Revenue | $44.0M | — | +125.9% |
| R&D Expense | $4.1M | — | +25.9% |
| SG&A Expense | $11.2M | — | +52.6% |
| Operating Income | -$2.7M | — | -3373.9% |
| Pre-tax Income | -$13.8M | — | — |
| Net Income | -$13.8M | — | — |
| EPS (Basic) | -$0.08 | — | +68.0% |
| EPS (Diluted) | -$0.08 | — | +68.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $38.9M | -11.8% | — |
| Accounts Receivable | $30.8M | -39.8% | — |
| Inventory | $1.4M | +9.5% | — |
| Current Assets | $111.6M | -17.2% | — |
| Total Assets | $213.1M | -11.7% | — |
| Current Liabilities | $188.2M | -14.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $1.9M | — | +652.3% |
| Investing Cash Flow | -$2.5M | — | — |
| Financing Cash Flow | -$4.6M | — | -2337.5% |
| Total Liabilities | $254.5M | -4.7% | +2666.3% |
| Stockholders' Equity | -$41.5M | -60.8% | -381.7% |